Viking Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX), a biopharmaceutical company focused on therapies for metabolic disorders, will participate in two upcoming investor conferences. On June 17, 2021, Viking will engage in 1-on-1 meetings at the SVB Leerink CybeRx Series: Liver Disease Day. Following that, from June 21-23, 2021, they will host a panel discussion on June 23 at 12:00 p.m. Eastern during the Raymond James Human Health Innovations Conference. Viking is also developing innovative drugs like VK2809 for NASH and VK0214 for X-ALD, aiming to enhance patient outcomes.

SAN DIEGO, Calif., June 10, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. 

Details of the company's participation are as follows:

• SVB Leerink CybeRx Series: Liver Disease Day
  Details: Viking management will participate in 1-on-1 meetings
  Conference Date: June 17, 2021 
  Format: Virtual Conference
   
   
• Raymond James Human Health Innovations Conference
  Details: Viking management will participate in a panel discussion and 1-on-1 meetings
  Conference dates: June 21-23, 2021
  Panel Discussion Timing: 12:00 p.m. Eastern on Wednesday, June 23, 2021
  Format: Virtual conference

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial.  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301309290.html

SOURCE Viking Therapeutics, Inc.

FAQ

What events will Viking Therapeutics participate in during June 2021?

Viking Therapeutics will participate in the SVB Leerink CybeRx Series: Liver Disease Day on June 17, 2021, and the Raymond James Human Health Innovations Conference from June 21-23, 2021.

What is the format of the upcoming investor conferences for Viking Therapeutics?

Both conferences will be conducted virtually, with Viking management participating in 1-on-1 meetings and a panel discussion.

When is the panel discussion for Viking Therapeutics at the Raymond James conference?

The panel discussion is scheduled for June 23, 2021, at 12:00 p.m. Eastern.

What drugs are being developed by Viking Therapeutics?

Viking is developing VK2809 for non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD).

What progress has Viking Therapeutics made with VK2809?

VK2809 has shown statistically significant reductions in LDL-C and liver fat content in Phase 2 trials for non-alcoholic fatty liver disease.